C4 Therapeutics, Inc. · NASDAQ:CCCC
Anderson Kenneth Carl received 2,650 C4 Therapeutics, Inc. shares as an award (Form 4)
Traded Jul 1, 2026 · Filed Jul 2, 2026
On Jul 1, 2026, Anderson Kenneth Carl (Director) received 2,650 C4 Therapeutics, Inc. shares as an award at US$4.34 for US$11,501, leaving 71,950 shares. Filed Jul 2, 2026 (Form 4).
- Awarded
- 2,650 shares
- Price
- US$4.34
- Value
- US$11,501
- Holding after
- 71,950 shares
- Trading plan
- No
- Role
- Director
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Jul 1, 2026 | Common Stock | Award | 2,650 | US$4.34 | 71,950 | Direct |
Source
Related
- C4 Therapeutics, Inc.
- Anderson Kenneth Carl
- C4 Therapeutics, Inc. shareholders
- Form 4 · Anderson Kenneth Carl · Oct 2, 2026
- Form 4 · Anderson Kenneth Carl · Jun 4, 2026
- Form 4 · Anderson Kenneth Carl · Apr 3, 2026
- Form 4 · Grogan Donna Roy · Oct 2, 2026
- Form 4 · Adams Kendra · Sep 21, 2026
- Schedule 13G/A · Lynx1 Capital Management LP · Aug 14, 2026
- Schedule 13G/A · Squadron Capital Management LLC · Aug 14, 2026
- Schedule 13G/A · Ra Capital Management, L.P. · Aug 14, 2026